Table 2.
Most frequent occurring treatment emerging adverse events
| Event | Gln-1062 5.5 mg | Gln-1062 11 mg | Gln-1062 22 mg | Gln-1062 33 mg | Gln-1062 44 mg | Galantamine 16 mg | Donepezil 10 mg | Placebo |
|---|---|---|---|---|---|---|---|---|
| Any event | 6 (100) | 6 (100) | 5 (83.3) | 5 (83.3) | 5 (83.3) | 10 (83.3) | 3 (50) | 5 (50) |
| Nasal discomfort | 6 (100) | 6 (100) | 4 (66.7) | 4 (66.7) | 3 (50) | — | 1 (16.7) | — |
| Rhinorrhea | 2 (33.3) | 4 (66.7) | 2 (33.3) | 1 (16.7) | 3 (50) | — | — | — |
| Sneezing | 1 (16.7) | 1 (16.7) | 1 (16.7) | 1 (16.7) | 3 (50) | — | — | — |
| Nausea | — | 1 (16.7) | 1 (16.7) | 3 (50) | 3 (50) | 4 (33.3) | 1 (16.7) | — |
| Vomiting | — | 1 (16.7) | — | 2 (33.3) | 2 (33.3) | 5 (41.7) | 1 (16.7) | 1 (10) |
| Diarrhea | — | — | 1 (16.7) | 1 (16.7) | 1 (16.7) | 1 (8.3) | 2 (33.3) | — |
| Cold sweat or hyperhidrosis | — | 1 (16.7) | — | — | 3 (50) | 4 (33.3) | — | — |
| Headache | 2 (33.3) | 2 (33.3) | 3 (50) | 2 (33.3) | — | 1 (8.3) | 2 (33.3) | 3 (30) |
NOTE. Number of subjects, percentage in parentheses.